The diabetes drug that cuts migraines in half and could help millions worldwide
A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study
Migraines can be, at best, an inconvenience and, at worst, totally debilitating. Your work rate and relationships can suffer when you're not feeling yourself.
And when pills and painkillers don't touch the sides, it can be hard knowing where to turn. However, a common diabetes drug may be the next big thing for migraine relief, according to an interesting new study.
In fact, the diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half. The findings from the clinical study were presented at the European Academy of Neurology (EAN) Congress 2025.
As part of the research, obese patients with chronic migraines who took liraglutide, a GLP-1 receptor agonist, experienced over 50 per cent fewer headache days and significantly improved daily functioning without meaningful weight loss.
Researchers believe the drug's ability to lower brain fluid pressure is the key, potentially opening a completely new way to treat migraines. The effects were fast, sustained, and came with only mild side effects.
"Most patients felt better within the first two weeks and reported quality of life improved significantly," said lead researcher Dr Simone Braca.
"The benefit lasted for the full three-month observation period, even though weight loss was modest and statistically non-significant."
Researchers at the Headache Centre of the University of Naples Federico II gave GLP-1 receptor agonist liraglutide to 26 adults with obesity and chronic migraine - which is when you have more than 15 headaches a month.
Afterwards, patients reported having 11 fewer headaches per month, while their work, study, and sociability got significantly better.
What's more, although the patients also lost a bit of weight - with their BMI dropping slightly from 34.01 to 33.65 - this was found to have had no link to how often they experienced headaches.
This strengthened the study's belief that pressure modulation, not weight loss, is behind the improvement.
"We think that... these drugs produce a decrease in the release of calcitonin gene-related peptide (CGRP), a key migraine-promoting peptide," Dr Braca explained.
"That would pose intracranial pressure control as a brand-new, pharmacologically targetable pathway."
Mild side effects, mainly nausea and constipation, occurred in 38 per cent of participants, but it did not force them to drop out of the 12-week study.
Off the back of the study, a randomised, double-blind trial is now being planned by the same research team in Naples.
"We also want to determine whether other GLP-1 drugs can deliver the same relief, possibly with even fewer gastrointestinal side effects," Dr Braca added.
If confirmed, GLP-1-receptor agonists could offer a new treatment option for the estimated one in seven people worldwide who live with migraine, particularly those who do not respond to current preventives.
Join the Daily Record WhatsApp community!
Get the latest news sent straight to your messages by joining our WhatsApp community today.
You'll receive daily updates on breaking news as well as the top headlines across Scotland.
No one will be able to see who is signed up and no one can send messages except the Daily Record team.
All you have to do is click here if you're on mobile, select 'Join Community' and you're in!
If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'.
We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like.
To leave our community click on the name at the top of your screen and choose 'exit group'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Record
19 hours ago
- Daily Record
The diabetes drug that cuts migraines in half and could help millions worldwide
A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study Migraines can be, at best, an inconvenience and, at worst, totally debilitating. Your work rate and relationships can suffer when you're not feeling yourself. And when pills and painkillers don't touch the sides, it can be hard knowing where to turn. However, a common diabetes drug may be the next big thing for migraine relief, according to an interesting new study. In fact, the diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half. The findings from the clinical study were presented at the European Academy of Neurology (EAN) Congress 2025. As part of the research, obese patients with chronic migraines who took liraglutide, a GLP-1 receptor agonist, experienced over 50 per cent fewer headache days and significantly improved daily functioning without meaningful weight loss. Researchers believe the drug's ability to lower brain fluid pressure is the key, potentially opening a completely new way to treat migraines. The effects were fast, sustained, and came with only mild side effects. "Most patients felt better within the first two weeks and reported quality of life improved significantly," said lead researcher Dr Simone Braca. "The benefit lasted for the full three-month observation period, even though weight loss was modest and statistically non-significant." Researchers at the Headache Centre of the University of Naples Federico II gave GLP-1 receptor agonist liraglutide to 26 adults with obesity and chronic migraine - which is when you have more than 15 headaches a month. Afterwards, patients reported having 11 fewer headaches per month, while their work, study, and sociability got significantly better. What's more, although the patients also lost a bit of weight - with their BMI dropping slightly from 34.01 to 33.65 - this was found to have had no link to how often they experienced headaches. This strengthened the study's belief that pressure modulation, not weight loss, is behind the improvement. "We think that... these drugs produce a decrease in the release of calcitonin gene-related peptide (CGRP), a key migraine-promoting peptide," Dr Braca explained. "That would pose intracranial pressure control as a brand-new, pharmacologically targetable pathway." Mild side effects, mainly nausea and constipation, occurred in 38 per cent of participants, but it did not force them to drop out of the 12-week study. Off the back of the study, a randomised, double-blind trial is now being planned by the same research team in Naples. "We also want to determine whether other GLP-1 drugs can deliver the same relief, possibly with even fewer gastrointestinal side effects," Dr Braca added. If confirmed, GLP-1-receptor agonists could offer a new treatment option for the estimated one in seven people worldwide who live with migraine, particularly those who do not respond to current preventives. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'.
Glasgow Times
a day ago
- Glasgow Times
Why am I not losing weight on Mounjaro, ask a fifth of users
While many have found GLP-1 treatments to help shed pounds quickly, others have reported struggling, with around a fifth not losing the weight they'd expected. Weight loss plateaus are common, but in many cases, the reasons are identifiable and fixable, say doctors. The new weight management medication 'Tirzepatide' (brand name Mounjaro®) is shortly being made available to NHS patients to support weight loss. Access is prioritised for those with the greatest clinical need. You can find out more at: — NHS Cheshire and Merseyside (@NHSCandM) June 24, 2025 'While Mounjaro is an effective medication for weight loss, it's normal to encounter a plateau at some point," says Dr. Crystal Wyllie from online health service Zava. "To enhance your results, it's important to follow the prescribed dosing schedule and aim to reach the appropriate maintenance dose, as higher doses are generally associated with greater benefits. However, if you're experiencing side effects, it's perfectly acceptable to step up more slowly. "Your GP may recommend staying on a lower dose for longer until your body adjusts, comfort and tolerability should always guide the pace of titration. "Beyond medication, factors like maintaining a balanced diet, regular physical activity, managing stress, and getting enough sleep play a vital role in supporting your weight loss journey. If progress stalls despite these efforts, consulting your healthcare provider is essential to evaluate your plan and make necessary adjustments. "For individuals who find Mounjaro less effective or unsuitable, there are several other weight loss medications to consider. Injectable options like Wegovy and Nevolat work similarly by curbing appetite, while oral medications such as Orlistat, Xenical, and the over-the-counter Alli provide different mechanisms to support weight loss. Each treatment has unique advantages and considerations, so working closely with your doctor ensures you receive the safest and most personalised approach to achieve your goals.' Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: — We are Primary Care (@PrimaryCareNHS) June 27, 2025 Zava say there are the most common reasons the weight loss injection Mounjaro may not be working as expected, and what you can do to get back on track. Incorrect medication use or dosage Mounjaro's effectiveness often increases as you move up the dosage ladder. The medication is typically titrated slowly to reduce side effects, eventually reaching maintenance doses of up to 15mg per week. If you're still on a lower dose or haven't advanced as recommended, your weight loss may be limited. Consistency is crucial. Skipping doses, delaying titration, or not following your provider's schedule can reduce the medication's impact. Many people don't feel the full effect until 8–12 weeks in, so patience and adherence are key. You should give Mounjaro at least three months before judging its effectiveness. If you're experiencing side effects, it's absolutely fine to remain at a lower dose for longer. ZAVA healthcare providers advise stepping up more slowly if you're not tolerating side effects well, there's no need to push through discomfort. You can always increase the dose later once your body has adjusted. Comfort and tolerability are just as important as consistency for long-term success. Poor diet and lack of exercise While Mounjaro helps reduce appetite, it doesn't override the fundamental rule of weight loss: you must burn more calories than you consume. Even with a smaller appetite, eating more than your body needs will still cause progress to stall. To maintain an effective calorie deficit for weight loss, men are generally advised to consume around 1,900 calories per day (down from the typical 2,500), while women should aim for about 1,400 calories per day (down from around 2,000). Healthy diet tips: Be strict with calorie tracking until portion control becomes second nature Aim for a 600-calorie daily deficit to lose weight steadily Prioritise whole foods over high-sugar, high-fat processed options Follow a diet plan tailored to your needs, and explore healthy recipe ideas to stay on track Also, remember that initial weight loss may come from water, especially if you've reduced salt or started exercising. As your body adjusts, weight loss may temporarily plateau or appear to reverse. Finally, stay hydrated and limit alcohol. Alcohol can interfere with your metabolism and reduce the effectiveness of Mounjaro. 🧵Weight loss jab roll out 'positive for patients' but with implications for general practice that must be considered. Our Chair Kamila Hawthorne has featured widely in the national press and broadcast media responding to the phased roll-out of Mounjaro prescriptions by NHS… — Royal College of General Practitioners (@rcgp) June 23, 2025 Stress and sleep issues Chronic stress and poor sleep are major weight loss blockers. Stress increases cortisol, a hormone linked to fat retention, especially around the abdomen. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (fullness hormone), making you more likely to overeat and less likely to move. You're also more impulsive and less motivated when sleep-deprived, making it harder to stick to your diet and exercise routine. As a solution, prioritise stress management techniques (like mindfulness or journaling), and aim for 7-9 hours of sleep per night. Health conditions and medications Medical issues such as PCOS, diabetes, hypothyroidism, or insulin resistance can all interfere with weight loss. Similarly, certain medications (like antidepressants or steroids) may cause weight gain or inhibit fat loss. If weight loss stalls despite doing everything right, consult your GP to rule out or address any underlying conditions. If you have a known medical condition, it's important to stay up to date with your routine reviews and inform your GP or specialist about any weight loss treatments you're using. Regular follow-up helps ensure your treatment plan remains safe and effective. More Mounjaro news... Unrealistic expectations It's natural to hope for rapid results, especially with a promising medication like Mounjaro. But weight loss is a long-term process. Initial drops (often water weight) can be misleading. Progress will slow, and that's okay. Avoid comparing yourself to others or obsessively checking the scale. Focus on consistency, not speed. Your journey is unique, and sustainable weight loss takes time. Lack of support Motivation by itself often isn't enough. Without support from those who understand your goals, the journey can feel lonely and overwhelming. Lean on friends and family who encourage you Join online communities or local support groups, including NHS-recommended programs Consider working with a dietitian or coach for personalised guidance and accountability Before beginning any weight loss treatment, please consult your GP or healthcare professional. These treatments may not be suitable for everyone.
Daily Mirror
a day ago
- Daily Mirror
NHS weight loss jabs might 'not be suitable' for these 5 groups
GPs will be prescribing Mounjaro to a select few people as the rollout begins, but others may need to avoid the jabs completely GPs can now prescribe Mounjaro, but only to a select group of patients who meet stringent criteria, such as having a BMI over 40 and being diagnosed with four out of five qualifying conditions. But people with other pre-existing conditions may not be able to access this weight loss drug at all. Dr Crystal Willie from ZAVA clarified that weight loss drugs "may be unsafe depending on medications you are taking or pre-existing medical conditions". This includes three specific conditions: Pancreatic disorders like pancreatitis History of thyroid cancer History of gallbladder disease Women who are pregnant, breastfeeding or planning to do either might also be advised to avoid the medication. The same goes for people on certain medications like insulin or immunosuppressants. Dr Willie told the Mirror: "You should speak to your doctor about any conditions or medications before taking any weight loss injection. Mounjaro weight loss injections can lower your blood sugar levels too much if taken in combination with sulfonylurea or insulin (other diabetes treatments). "You shouldn't take Mounjaro alongside other weight loss injections, such as Saxenda or Wegovy. This could increase the risk of serious health risks and side effects." The doctor also revealed that weight loss medication might actually not do what people think, as research from ZAVA found up to 20% of people using the GLP-1 drugs don't see the expected results or hit a weight loss plateau. There are a variety of reasons for this, including: Incorrect dosage Missing doses Not improving your diet and an inactive lifestyle Not keeping hydrated Excessive alcohol consumption Persistent stress Having a poor sleep routine Other health conditions may interfere with the effectiveness of weight loss drugs, like diabetes, hypothyroidism, insulin resistance and PCOS. Medications like antidepressants or steroids may also cause weight gain or hinder fat loss. Dr Wyllie added: "While Mounjaro is an effective medication for weight loss, it's normal to encounter a plateau at some point. To enhance your results, it's important to follow the prescribed dosing schedule and aim to reach the appropriate maintenance dose, as higher doses are generally associated with greater benefits. "Beyond medication, factors like maintaining a balanced diet, regular physical activity, managing stress, and getting enough sleep play a crucial role in supporting your weight loss journey. If progress stalls despite these efforts, consulting your healthcare provider is essential to evaluate your plan and make necessary adjustments."
